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The FDA’s Guidance on Dietary
Supplement Naming
and the Emperor’s New Clothes
Neal D. Fortin

I. Introduction
What do a Food and Drug Administration (FDA) guidance
document and a Hans Christian Andersen fable have in
common? Unfortunately, more than one might hope.
The fable of the emperor’s new clothes is iconic for the
human tendency towards collective avoidance of speaking truth
to power. The fable is also a metaphor for smooth-talking
tricksters hoodwinking a government leader.
A recent FDA guidance document indicates one or both of
these failings. On March 7, 2016, FDA published a notice in the
Federal Register, stating that it was revising the agency’s
guidance on dietary supplement labeling.1 The reason for the
revision, FDA declared, was that the agency was, “made aware
that the guidance was inaccurate in one detail.”2 FDA’s
modification of this detail—the new clothes—permits dietary
supplements to be generically labeled. Specifically, FDA states,
“the term ‘dietary supplement’ may be used as the entire
statement of identity for a dietary supplement”.3
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1. A Dietary Supplement Labeling Guide: Chapter II. Identity Statement; Guidance
for Industry; Availability, 81 Fed. Reg. 11,813, 11,814 (Mar. 7, 2016).
2. Id. at 11,814.
3. Id. (emphasis added).
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Who the smooth-talking weavers were who sold FDA this
invisible garment is not transparent. Nonetheless, it is
transparent that the FDA’s “correction” is in clear error. The
original 2005 guidance language was accurate based on the
following:
- the plain language of the Food, Drug, and Cosmetic Act;
- the plain language of 21 C.F.R. § 101.3(g); and
- even if one accepts, arguendo, that the law is ambiguous,
the new interpretation does not comport with numerous
rules of statutory interpretation.
Moreover, this change violates the Administrative Procedures
Act and the FDA’s rules on notice and comment. This change is
a disguised rescission of 21 C.F.R. § 101.3(g) without a proper
opportunity for the public to be heard under notice and comment
rulemaking.

II. Interpretation of the Law on Dietary
Supplement Naming
A. The 2005 Guidance Accurately Interpreted the
Plain Language of the Statute
The starting point for analysis is the text of the statute.4 The
Federal Food, Drug, and Cosmetic Act states that a dietary
supplement is misbranded if: “the label or labeling of the dietary
supplement fails to identify the product by using the term
‘dietary supplement’, which term may be modified with the
name of such an ingredient.”5 Thus, the term “dietary
supplement” or the modification must be included in the
identification of a dietary supplement. This is how dietary
supplements are distinguished from conventional foods.
Nothing in the wording indicates that “dietary supplement”
is or can be the entire statement of identity for the entire diverse
category of dietary supplements. Note the sleight of hand. The
requirement to identify dietary supplements as dietary
supplements disappears. In its place is substituted the creation of
4. See, e.g., Desert Palace, Inc. v. Costa, 539 U.S. 90, 98 (2003) (“Our precedents
make clear that the starting point for our analysis is the statutory text.”).
5. Federal Food, Drug, and Cosmetic Act 21 U.S.C.A. § 343(s)(2)(B) (2010)
[hereinafter FDCA or Act].
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a statement of identity requirement for dietary supplements. By
way of illustration, with a category of conventional food, all
cheeses must be identified as cheese, but “cheese” is not the
complete statement of identity for all cheeses.
Because the meaning of the language of the statute is
unambiguous, further construction of the language is normally
neither necessary nor permitted.6 Any deference to the agency
interpretation of the statute is lost when that interpretation is
contrary to the plain meaning of the statute or is unreasonable.7
The plain meaning of the Food, Drug, and Cosmetic Act is that
the term “dietary supplement” or a modification must be
included within the identification of a dietary supplement, but
nothing in the Act’s wording indicates that the term may be a
complete statement of identity.

B. The 2005 Guidance Accurately Interpreted the
Plain Language of the Regulation
The plain language in FDA regulation 21 C.F.R. § 101.3(g)
is clear that the term “dietary supplement” or a modification
must be included in the identity of a dietary supplement. Also
clear from the regulation is that the term “dietary supplement,”
is not a complete statement of identity. The FDA rule, 21 C.F.R.
§ 101.3(g), reads:
(g) Dietary supplements shall be identified by the term
“dietary supplement” as a part of the statement of identity,
except that the word “dietary” may be deleted and replaced
by the name of the dietary ingredients in the product (e.g.,
calcium supplement) or an appropriately descriptive term
indicating the type of dietary ingredients that are in the
product (e.g., herbal supplement with vitamins).8

The language of the regulation plainly contradicts the FDA’s
“correction” in the March 7, 2016, Federal Register. The
“dietary supplement” is a part of the statement of identity and
therefore cannot be the entire statement of identity. Even the
6. See, id.; Connecticut Nat. Bank v. Germain, 503 U. S. 249, 253-254 (1992)
(“When the words of the statute are unambiguous, the ‘judicial inquiry is complete.’”
(quoting Rubin v. United States, 449 U. S. 424, 430 (1981)).
7. See Sullivan v. Everhart, 494 U.S. 83, 88-89 (1990) (citing Chevron U.S.A. Inc. v.
Natural Resources Defense Council, Inc., 467 U.S. 837, 842–43 (1984)).
8. 21 C.F.R. § 101.3(g) (emphasis added).
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most tortuous reading of the regulation cannot support the
FDA’s erroneous “correction.”

C. Even if One Accepts, Arguendo, That the Phrase
is Ambiguous, the New Interpretation Does not
Comport With the Rules of Statutory Interpretation
1. Interpret the Language Within the Context of the
Provision
Any exercise of statutory construction must be made within
the context of the whole statute.9 Statutory interpretation is a
“holistic endeavor”.10
The context for the provision in question in the Federal
Food, Drug, and Cosmetic Act (FDCA) § 403(s), states that a
dietary supplement is misbranded if:
(1) it is a dietary supplement; and
(2)(A) the label or labeling of the supplement fails to list—
(i) the name of each ingredient of the supplement that
is described in section 321(ff) of this title; and
(ii)(I) the quantity of each such ingredient; or (II) with
respect to a proprietary blend of such ingredients, the
total quantity of all ingredients in the blend;
(B) the label or labeling of the dietary supplement fails
to identify the product by using the term “dietary
supplement”, which term may be modified with the name
of such an ingredient.11

This part of the FDCA describes certain details that must be
included on a dietary supplement label or the product will be
misbranded. These details are not the beginning and end of the
labeling requirements for dietary supplements; there are many
other labeling requirements elsewhere in the FDCA that apply to

9. See John Hancock Mut. Life Ins. Co. v. Harris Trust & Sav. Bank, 510 U.S. 86,
94-95 (1993); see also Massachusetts v. Morash, 490 U.S. 107, 115 (1989) (“‘[I]n
expounding a statute, we [are] not . . . guided by a single sentence or member of a sentence,
but look to the provisions of the whole law, and to its object and policy.’”).
10. See Smith v. United States, 508 U.S. 223, 233(1993) (quoting United Sav. Assn.
v. Timbers of Inwood Forest Assocs., Ltd., 484 U.S. 365, 371 (1988).
11. 21 U.S.C.A § 343(s) (2010).
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dietary supplements.12 Clearly, this unique dietary supplement
requirement is intended to be read in conjunction with other
general labeling requirements in the Food, Drug, and Cosmetic
Act. Specifically, the above provision relates to some unique
aspects of the dietary supplement label that distinguish it from
conventional foods.
Nothing in the context concerns overall naming of dietary
supplements. Nowhere does the language even use the term
“statement of identity.” Within this context, there is no
ambiguity in the language in the Act. The plain language
indicates terms that, if absent from the label, will result in a
misbranded product. Nothing more.

2. If Need be, Interpret the Language Within the
Overarching Purpose of the Act
The 1938 Food, Drug, and Cosmetic Act’s primary purpose
is to protect consumer’s health, as well as their pocketbooks.
The latter purpose included a provision requiring that food “bear
its common or usual name,” which was added in 1938 in large
part so that consumers could make value comparisons in the
marketplace. Allowing a generic statement of identity for all
countless, varied dietary supplements is contrary to the purpose
of the Act.13 Clearly, Congress never intended § 403(s)(2)(B) to
limit the FDA’s ability to require truthful, informative labeling
of the statement of identity of dietary supplements. Statutes,
when ambiguous, should be interpreted so as best to carry out
their statutory purpose.14

3. Reconcile With Other Provisions of the Act to
Produce a Harmonious Whole
Any interpretation must be read in the context of the entire
statute so as to produce a harmonious whole.15 Section 403(i)(1)
12. See, e.g., 21 U.S.C.A. § 343-2(a); 21 U.S.C.A. § 342(g); 21 U.S.C.A. § 379aa1(b).
13. See NEAL FORTIN, FOOD REGULATION: LAW, SCIENCE, POLICY, AND PRACTICE
31 (Wiley, 2d ed. 2017).
14. See Reves v. Ernst & Young, 494 U.S. 56, 60-61 (1990).
15. See United Sav. Assn. v. Timbers of Inwood Forest Assocs., Ltd., 484 U.S. 365,
371 (1988) (favors a meaning that produces a substantive effect compatible with the rest of
the law).
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of the Act requires that a food label must bear the common or
usual name of the food.16 The generic term, “dietary
supplement,” is not the common or usual name of all dietary
supplements.17 “Dietary supplement” is the name of the entire
regulatory category rather than the common or usual name or
any specific food.18

4. The Rule of Continuity
Similar to the favoring of harmonious interpretation, the
rule of continuity directs us to assume that Congress does not
discontinue duties or obligations without some clear statement.19
Nothing in the statute or the legislative history indicates that
Congress intended to repeal the obligation that dietary
supplements be labeled under the general requirements for a
statement of identity for packaged food (including dietary
supplements, which are a subcategory of “food” under the Act).
In particular, exemptions from other statutory requirements
should be read narrowly.20

5. Repeal by Implication Disfavored
To reconcile FDA’s current interpretation with other
provisions of the Act would require negating the FDCA
requirement for a statement of identity for dietary
supplements.21 If Congress had intended such major change in
the law, the language of the statute would have indicated it. It is
absurd to believe that Congress sub silentio suspended section
403(i)(1) of the Food, Drug, and Cosmetic Act from application
16. FDCA 21 U.S.C. § 403(i)(1).
17. Brian Scarbrough, Dietary Supplements: A Review of United States Regulation
with Emphasis on the Dietary Supplement Health and Education Act of 1994 and
Subsequent Activity, DIGITAL ACCESS TO SCHOLARSHIP AT HARV. (Nov. 14, 2017), https://
dash.harvard.edu/bitstream/handle/1/8852160/scarbrough.pdf?sequence=1.
18. Id.
19. See Green v. Bock Laundry Mach. Co., 490 U.S. 504, 521 (1989) (“A party
contending that legislative action changed settled law has the burden of showing that the
legislature intended such a change.”); see also Finley v. United States, 490 U.S. 545, 554
(1989) (“Under established canons of statutory construction, ‘it will not be inferred that
Congress, in revising and consolidating the laws, intended to change their effect unless
such intention is clearly expressed.’” (quoting, Anderson v. Pacific Coast S.S. Co., 225
U.S. 187, 199 (1912)).
20. See, e.g., Commissioner v. Clark, 489 U.S. 726, 739 (1989).
21. FDCA § 403(i)(1).
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to dietary supplements. As a rule, exemptions or exceptions to
the general requirements of an act are not created unless
specified by Congress.22

6. The “Dog Didn’t Bark” Canon
Similar to the rule disfavoring repeal of requirements,
without express statutory language is the “dog didn’t bark”
canon. The presumption is that a prior legal rule should be
retained if no one in legislative deliberations discussed any
changes in the rule.23

7. Avoid Unreasonable Results
Under the FDA revised guidance, statements of identity on
dietary supplement labels could be changed as follows:
Current statement of identity

Permitted statement of
identity under FDA’s
new guidance
Garlic 1000 mg Supplement
dietary supplement
Fiber Supplement
dietary supplement
Iron Supplement 65 mg
dietary supplement
Multivitamin Supplement
dietary supplement
Ginger root dietary supplement
dietary supplement
D3 1000 IU dietary supplement
dietary supplement
Lutein 20 mg dietary supplement
dietary supplement
Fish Oil 1200 mg dietary supplement
dietary supplement
Statutory language should be construed reasonably. The new
FDA interpretation is unreasonable.

8. Apply Common Sense
An interpretation of the statute should comport with
common sense. FDA’s new guidance creates an absurd result.

22. See United States v. Smith, 499 U.S. 160, 166-67 (1991).
23. See Chisom v. Roemer, 501 U.S. 380, 396 n.23 (1991) (“Congress’ silence in this
regard can be likened to the dog that did not bark.” See A. DOYLE, SILVER BLAZE, in THE
COMPLETE SHERLOCK HOLMES 335 (1927)).
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9. Review the Legislative History and
Contemporaneous Interpretation
The primary goal of judicial interpretation of statutes is to
ascertain and give effect to the intent of the legislature. In 1996,
the FDA received numerous comments on its proposed new rule
21 C.F.R. § 101.3(g).24 Nowhere in the legislative history did
anyone construe the meaning of section 403(s)(2)(B) of the
FDCA as supplying the complete statement of identity. All 1996
discussion revolved around including “dietary supplement” as
part of the statement of identity. For example, “The agency has
carefully reviewed these comments but concludes that the best
reading of the act, as well as the agency’s longstanding
regulations that implement the act, require that the term ‘dietary
supplement,’ or some form of this term, appear as part of the
statement of identity.”25

III. FDA’s Violation of the Administrative
Procedures Act
A. Failure to Give Notice and Comment
This change violates the Administrative Procedures Act
and FDA’s rules on notice and comment.

B. Disguised Rescission of a Rule Without Proper
Notice and Comment
FDA’s change is a disguised rescission of 21 C.F.R. §
101.3(g) without a proper opportunity to be heard under notice
and comment rulemaking in violation of the Administrative
Procedures Act section 553. The FDA rule 21 C.F.R. § 101.3(g)
clearly identifies that the term “dietary supplement” is only a
part of the statement of identity for a dietary supplement. The
FDA’s new guidance statement effectively negates 21 C.F.R. §
101.3(g) without the required rescission or amendment of the
rule.
24. Food Labeling: Statement of Identity, Nutrition Labeling and Ingredient Labeling
of Dietary Supplements; Compliance Policy Guide, Revocation, 62 Fed. Reg. 49,826 (Sept.
23, 1997) (to be codified at 21 C.F.R. pt. 101).
25. Id. at 49,827.
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In addition, this was a major change that should have had
public participation—in accordance with FDA rule 21 C.F.R. §
10.115(g)(2)—before it was instituted. Changing the
longstanding meaning of the guidance and effectively negating
the plain language of the FDA’s rule of 21 C.F.R. § 101.3(g)
was a major change that required public participation through
notice and comment before it could be effectuated.
The April 2005 FDA guidance for industry, “A Dietary
Supplement Labeling Guide,” was accurate. Therefore, FDA
should immediately reinstate the April 2005 guidance language
on this detail. Specifically, in Chapter II, Identity Statement,
question 3 asked, “Can the term ‘dietary supplement’ by itself
be considered the statement of identity?” The 2005 response to
the question said that it could not. This interpretation is
consistent with the plain meaning of section 403(s)(2)(B) of the
Federal Food, Drug, and Cosmetic Act and 21 C.F.R. §
101.3(g).

IV. Conclusion
To be candid, no one wants to see the emperor naked. It is
unseemly, undermines respect, and is, frankly, more than a little
disturbing. FDA must remedy this situation immediately. No
matter how humiliating it might be for FDA to admit it has no
clothes, recognizing the truth beats walking around naked.
The truth of the law regarding the naming of dietary
supplements is clear. The FDA’s new guidance regarding the
statement of identity for dietary supplements leaves the agency
naked with not even a fig leaf to cover itself. Moreover, FDA is
breaking the law on notice and comment rulemaking.
What is not clear is why FDA made such a blatant and
obvious error of law. How much of the metaphor of the
emperor’s new clothes applies? Is FDA collectively avoiding
speaking truth regarding the new guidance? Or did FDA get
hoodwinked by a smooth-talking trickster? More troubling than
naked leadership on a small matter is what the mistake might
reveal about the state of this important federal agency.

